Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 25;112(4):335–342. doi: 10.1093/jnci/djz211

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

PMC Copyright notice

Figure 1. — Forest plots of cumulative meta-analysis on the effect of bevacizumab on progression-free survival (PFS) and overall survival (OS). A) PFS and B) OS panels show cumulative meta-analyses performed by adding individual trials chronologically and summarizing the point estimate as each new trial is added. The plus symbol before each trial indicates that the point estimate (ie, hazard ratio) of that trial is pooled with the previous summary estimate. The final result is a trial-level cumulative estimate over time and corresponding 95% confidence intervals. The diamonds represent the cumulative point estimates and the horizontal segments represent the 95% confidence intervals. Ctrl = number of participants in the control group; Cum. Ctrl = cumulative number of participants in the control group; Cum. Exp = cumulative number of participants in the experimental group; Exp = number of participants in the experimental group; OS = overall survival; PFS = progression-free survival.